

Laurens F Reeskamp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6244797/publications.pdf>

Version: 2024-02-01

32
papers

1,152
citations

471509

17
h-index

477307

29
g-index

34
all docs

34
docs citations

34
times ranked

1222
citing authors

#	ARTICLE	IF	CITATIONS
1	Evinacumab for Homozygous Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2020, 383, 711-720.	27.0	413
2	Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2020, 383, 1317-1327.	27.0	108
3	Combination lipid-lowering therapy as first-line strategy in very high-risk patients. <i>European Heart Journal</i> , 2022, 43, 830-833.	2.2	92
4	ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1753-1759.	2.4	60
5	Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2019, 280, 109-117.	0.8	40
6	Transintestinal cholesterol excretion in humans. <i>Current Opinion in Lipidology</i> , 2018, 29, 10-17.	2.7	35
7	Cardiovascular risk factors and COVID-19 outcomes in hospitalised patients: a prospective cohort study. <i>BMJ Open</i> , 2021, 11, e045482.	1.9	35
8	Marked plaque regression in homozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2021, 327, 13-17.	0.8	35
9	Taking One Step Back in Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 973-985.	2.4	33
10	The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?. <i>Current Opinion in Lipidology</i> , 2020, 31, 140-146.	2.7	29
11	Ethnicity, lipids and cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2017, 28, 225-230.	2.7	28
12	Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study. <i>Atherosclerosis</i> , 2022, 341, 43-49.	0.8	28
13	ABCG5 and ABCG8 genetic variants in familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2020, 14, 207-217.e7.	1.5	26
14	A Deep Intronic Variant in <i>LDLR</i> in Familial Hypercholesterolemia. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002385.	3.6	23
15	Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2567-2569.	2.8	23
16	Next-generation sequencing to confirm clinical familial hypercholesterolemia. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 875-883.	1.8	23
17	Novel lipid modifying drugs to lower LDL cholesterol. <i>Current Opinion in Lipidology</i> , 2017, 28, 367-373.	2.7	22
18	Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods. <i>Current Opinion in Lipidology</i> , 2020, 31, 347-355.	2.7	17

#	ARTICLE	IF	CITATIONS
19	Next-generation sequencing to confirm clinical familial hypercholesterolemia. <i>European Journal of Preventive Cardiology</i> , 2020, , 204748732094299.	1.8	12
20	Analysis and Optimization of Conditions for the Use of 2â€²,7â€²-Dichlorofluorescein Diacetate in Cultured Hepatocytes. <i>Antioxidants</i> , 2021, 10, 674.	5.1	12
21	Differential DNA methylation in familial hypercholesterolemia. <i>EBioMedicine</i> , 2020, 61, 103079.	6.1	10
22	Intronic variant screening with targeted next-generation sequencing reveals first pseudoexon in LDLR in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2021, 321, 14-20.	0.8	10
23	Intranasal corticosteroids for non-allergic rhinitis. <i>The Cochrane Library</i> , 2019, 2019, .	2.8	9
24	Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation. <i>Atherosclerosis</i> , 2020, 315, 68-75.	0.8	8
25	From evidence to practice: development of web-based Dutch lipid reference values. <i>Netherlands Heart Journal</i> , 2021, 29, 441-450.	0.8	6
26	Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia. <i>Atherosclerosis</i> , 2022, 340, 61-67.	0.8	6
27	Hepatocyte-like cells derived from induced pluripotent stem cells: A versatile tool to understand lipid disorders. <i>Atherosclerosis</i> , 2020, 303, 8-14.	0.8	5
28	PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 270-271.	1.8	2
29	Hypercholesterolemia Among Prematureâ€šInfarcts. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2451-2453.	2.8	1
30	EVINACUMAB MARKEDLY REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN ADOLESCENT PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA. <i>Journal of the American College of Cardiology</i> , 2021, 77, 121.	2.8	0
31	Reader response: Lipid levels and the risk of hemorrhagic stroke among women. <i>Neurology</i> , 2020, 94, 549.3-550.	1.1	0
32	Letter by Tromp et al Regarding Article, â€œLarge-Scale Screening for Monogenic and Clinically Defined Familial Hypercholesterolemia in Icelandâ€š. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, e44-e45.	2.4	0